Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials
Open Access
- 18 October 2021
- journal article
- review article
- Published by Elsevier in Neurotherapeutics
- Vol. 18 (4) , 2351-2367
Abstract
No abstract availableKeywords
This publication has 73 references indexed in Scilit:
- Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological DiseasesPLOS ONE, 2013
- Nerve growth factor and expression of its receptors in patients with diabetic neuropathyDiabetic Medicine, 2009
- CSF protein biomarkers for proximal axonal damage improve prognostic accuracy in the acute phase of Guillain‐Barré syndromeMuscle & Nerve, 2009
- Glial fibrillary acidic protein as a marker of axonal damage in chronic neuropathiesMuscle & Nerve, 2009
- Glial fibrillary acidic protein in Guillain‐Barré syndrome: Methodological issuesMuscle & Nerve, 2009
- Low serum levels of nerve growth factor in diabetic neuropathyActa Neurologica Scandinavica, 2009
- Glial fibrillary acidic protein: A marker of axonal Guillain–Barrè syndrome and outcomeMuscle & Nerve, 2008
- CSF neurofilament levels: A potential prognostic marker in Guillain–Barré syndromeNeurology, 2006
- Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapyAnnals of Oncology, 2004
- Osteopontin: A novel axon‐regulated Schwann cell geneJournal of Neuroscience Research, 2001